Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
作者： Chung-Kuan Wu , Shang-Jyh Kao , Hung-Chih Lai
DOI: 10.1016/J.JTHO.2018.01.025
关键词:
摘要:
jto.org
sci-hub.se 参考文章(5)
Yasuhide Yamada, Kazushi Yoshida, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study Translational lung cancer research. ,vol. 4, pp. 217- 219 ,(2015) , 10.3978/J.ISSN.2218-6751.2015.03.04
Mei Ji, Yan Liu, Qing Li, Xiao-Dong Li, Wei-Qing Zhao, Hanze Zhang, Xiaofei Zhang, Jing-Ting Jiang, Chang-Ping Wu, PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine. ,vol. 13, pp. 5- 5 ,(2015) , 10.1186/S12967-014-0373-0
Brett G.M. Hughes, Bryan A. Chan, Targeted therapy for non-small cell lung cancer: current standards and the promise of the future Translational lung cancer research. ,vol. 4, pp. 36- 54 ,(2015) , 10.3978/J.ISSN.2218-6751.2014.05.01
Paloma Martín Martorell, Marisol Huerta, Amparo Compañ Quilis, Rosario Abellán, Enrique Seda, Sebastián Blesa, Felipe J. Chaves, Diego Dualde Beltrán, Susana Roselló Keränen, José Franco, Amelia Insa, Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients Clinical Lung Cancer. ,vol. 18, ,(2017) , 10.1016/J.CLLC.2017.04.006
David P. Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn Juergens, Solange Peters, Elisa Minenza, John M. Wrangle, Delvys Rodriguez-Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejci, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski, First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer New England Journal of Medicine. ,vol. 376, pp. 2415- 2426 ,(2017) , 10.1056/NEJMOA1613493